drugset / Trial / NCT03478020

Oral AQX-1125 and Combination Oral Contraceptive Drug-Drug Interaction Study

NCT03478020

Phase 1 Completed 32 enrolled Aquinox Pharmaceuticals (Canada) Inc.
SequentialOpen-labelTreatment

Summary

This is an open-label, fixed sequence, 4 cycle, drug-drug interaction (DDI) study of AQX-1125 in healthy female subjects on combination oral contraceptives (COC).

Timeline

Start
2017-11-22
Primary completion
2018-03-29
Completion
2018-04-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Levonorgestrel Small molecule 100 ug Oral
Subject ROSIPTOR Small molecule 200 mg Oral
Subject ethinyl estradiol Small molecule 20 ug Oral

Indications

No indication recorded.